**According to the statutory prospectus dated 11/28/2015.
1The current expense ratio is an annualized calculation sourced by the Fund Administrator to the Fund, U.S. Bancorp Fund Services, LLC, using fiscal year-to-date (fiscal year-end is July 31) Fund expenses and Fund average net assets as of June 30, 2016. The current expense ratio referenced on the Fund’s site will be updated on a calendar year quarterly basis within 15 days after quarter-end. The most updated number can be obtained by calling 540-687-8925.
Performance data quoted represents past performance; past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than their original cost. Current performance of the fund may be lower or higher than the performance quoted. Performance data current to the most recent month end may be obtained by calling 1-877-862-9556. The Fund imposes a 1.00% redemption fee on shares held for 30 days or less. Performance data does not reflect the redemption fee. If it had, returns would be reduced.
The S&P 500 Index is an index of 500 large capitalization companies selected by Standard & Poor’s Corporation. One cannot invest directly in an index. Free cash flow (FCF) represents the cash that a company is able to generate after laying out the money required to maintain or expand its asset base.
Overall 5-Star Rating by Morningstar (AKREX and AKRIX) as of 06/30/16. Morningstar identifies the fund in the Mid-Cap Growth Category, which includes 650 funds for the given time period. The Overall Morningstar Rating™ for a fund is derived from weighted metrics, which are based on risk-adjusted return performance.
Akre Focus Beats the Market Again – Kiplinger’s
October 31, 2015
Akre Focus (AKREX)
September 1, 2014
Chuck Akre Interviewed on Consuelo Mack – WealthTrack
May 16, 2014
This Fund is on a Roll – Morningstar
February 4, 2014
Mutual fund investing involves risk. Principal loss is possible. The Fund is non-diversified, meaning it may focus its assets in fewer individual holdings than a diversified fund. Therefore, the Fund is more exposed to individual stock volatility than a diversified fund. The Fund invests in small- and medium-capitalization companies, which involve additional risks such as limited liquidity and greater volatility than larger capitalization companies. Download the prospectus.
Before you invest in the Akre Focus Fund, please refer to the Statutory Prospectus and Summary Prospectus for important information about the investment company, including investment objectives, risks, charges and expenses. You may also obtain a hard copy of the prospectus by calling 1-877-862-9556. The prospectus should be read and considered carefully before you invest or send money.
The Fund is offered only to United States residents, and information on this site is intended only for such persons. Nothing on this web site should be considered a solicitation to buy or an offer to sell shares of the Fund in any jurisdiction where the offer or solicitation would be unlawful under the securities laws of such jurisdiction.
The Akre Focus Fund is distributed by Quasar Distributors, LLC.
For each fund with at least a three-year history, Morningstar calculates a Morningstar Rating (based on a Morningstar risk-adjusted return measure that accounts for variation in a fund’s monthly performance, including the effects of sales charges, loads, and redemption fees), placing more emphasis on downward variations and rewarding consistent performance. The top 10% of funds in each category receive 5 stars, the next 22.5% receive 4 stars, the next 35% receive 3 stars, the next 22.5% receive 2 stars and the bottom 10% receive 1 star. The Akre Focus Fund Retail share class (AKREX) was rated 4-Star against 650 MidCap Growth funds over the last three years. The Akre Focus Fund Institutional share class (AKRIX) was rated 5-Star against 650 MidCap Growth funds over the last three years. The Akre Focus Fund (AKREX and AKRIX) was rated 5-Star against 573 MidCap Growth funds over the last five years.